- Home
- HAFC vs OPT Comparison
HAFC vs OPT Comparison
Compare HAFC & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFC
- OPT
- Stock Information
- Founded
- HAFC 1982
- OPT 1984
- Country
- HAFC United States
- OPT Australia
- Employees
- HAFC N/A
- OPT N/A
- Industry
- HAFC Major Banks
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAFC Finance
- OPT Health Care
- Exchange
- HAFC Nasdaq
- OPT Nasdaq
- Market Cap
- HAFC 774.8M
- OPT 767.9M
- IPO Year
- HAFC 1996
- OPT 2020
- Fundamental
- Price
- HAFC $25.75
- OPT $3.23
- Analyst Decision
- HAFC Buy
- OPT Strong Buy
- Analyst Count
- HAFC 6
- OPT 1
- Target Price
- HAFC $22.63
- OPT $12.00
- AVG Volume (30 Days)
- HAFC 212.0K
- OPT 35.9K
- Earning Date
- HAFC 10-22-2024
- OPT 08-30-2024
- Dividend Yield
- HAFC 3.88%
- OPT N/A
- EPS Growth
- HAFC N/A
- OPT N/A
- EPS
- HAFC 2.08
- OPT N/A
- Revenue
- HAFC $232,767,000.00
- OPT $261,859.00
- Revenue This Year
- HAFC N/A
- OPT N/A
- Revenue Next Year
- HAFC $11.40
- OPT $46,864.64
- P/E Ratio
- HAFC $12.40
- OPT N/A
- Revenue Growth
- HAFC N/A
- OPT N/A
- 52 Week Low
- HAFC $14.45
- OPT $1.79
- 52 Week High
- HAFC $26.30
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- HAFC 67.29
- OPT 28.00
- Support Level
- HAFC $25.01
- OPT $3.22
- Resistance Level
- HAFC $26.07
- OPT $3.37
- Average True Range (ATR)
- HAFC 0.76
- OPT 0.21
- MACD
- HAFC -0.05
- OPT -0.11
- Stochastic Oscillator
- HAFC 87.15
- OPT 9.92
About HAFC Hanmi Financial Corporation
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. Hanmi also offers trade-finance products. The bank has several lending offices outside California and plans to expand outside the state mainly through acquisitions. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.